SEARCH

SEARCH BY CITATION

References

  • 1
    Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999; 353:1689 94.DOI: 10.1016/s0140-6736(98)07422-4
  • 2
    O'Donnell MA & DeWolf WC. Bacillus Calmette–Guerin immunotherapy for superficial bladder cancer: new prospects for an old warhorse. Surg Oncol Clin North Am 1995; 4:189 202.
  • 3
    Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992; 19:573 80.
  • 4
    Steg A, Adjiman S, Debre B. BCG therapy in superficial bladder tumours—complications and precautions. Eur Urol 1992; 21 (Suppl. 2):35 40.
  • 5
    Williams RD. Intravesical interferon alfa in the treatment of superficial bladder cancer. Semin Oncol 1988; 15:10 13.
  • 6
    Belldegrun AS, Franklin JR, O'Donnell MA et al. Superficial bladder cancer: the role of interferon-alpha. J Urol 1998; 159:1793 801.
  • 7
    Naitoh J, Franklin J, O'Donnell MA, Belldegrun AS. Interferon alpha for the treatment of superficial bladder cancer. Adv Exp Med Biol 1999; 462:371 86.
  • 8
    Sargent ER & Williams RD. Immunotherapeutic alternatives in superficial bladder cancer: interferon, interleukin-2 and keyhole limpet hemocyanin. Urol Clin North Am 1992; 19:581 9.
  • 9
    Bercovich E, Deriu M, Manferrari F, Irianni G. BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder. Arch Ital Urol Androl 1995; 67:257 60.
  • 10
    Stricker P, Pryor K, Nicholson T et al. Bacillus Calmette–Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology 1996; 48:957 61.
  • 11
    Gan YH, Zhang Y, Khoo HE, Esuvaranathan K. Antitumor immunity of bacillus Calmette–Guerin and interferon alpha in murine bladder cancer. Eur J Cancer 1999; 35:1123 9.DOI: 10.1016/s0959-8049(99)00057-x
  • 12
    Sarosdy MF & Kierum CA. Combination immunotherapy of murine transitional cell cancer using BCG and an interferon-inducing pyrimidinone. J Urol 1989; 142:1376 9.
  • 13
    Luo Y, Chen X, Downs TM, DeWolf WC, O'Donnell MA. IFN-α 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette–Guerin immunotherapy . J Immunol 1999; 162:2399 405.
  • 14
    Pryor K, Stricker P, Russell P, Golovsky D, Penny R. Antiproliferative effects of bacillus Calmette–Guerin and interferon-α 2b on human bladder cancer cells in vitro. Cancer Immunol Immunother 1995; 41:309 16.DOI: 10.1007/s002620050233
  • 15
    Zhang Y, Khoo HE, Esuvaranathan K. Effects of bacillus Calmette–Guerin and interferon alpha-2B on cytokine production in human bladder cancer cell lines. J Urol 1999; 161:977 83.
  • 16
    O'Donnell MA, Aldovini A, Duda RB, Yang H, Szilvasi A, Young RA, DeWolf WC. Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 1994; 62:2508 14.
  • 17
    O'Donnell MA. The genetic reconstruction of BCG as a new immunotherapeutic tool. Trends Biotechnol 1997; 15:512 7.DOI: 10.1016/s0167-7799(97)01134-7
  • 18
    Luo Y, Szilvasi A, Chen X, DeWolf WC, O'Donnell MA. A novel method for monitoring Mycobacterium bovis BCG trafficking using recombinant BCG expressing green fluorescent protein. Clin Diag Lab Immunol 1996; 3:761 8.
  • 19
    Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leuk Biol 1997; 61:246 57.
  • 20
    Ratliff TL. Role of the immune response in BCG for bladder cancer. Eur Urol 1992; 21 (Suppl. 2):17 21.
  • 21
    Bowyer L, Hall RR, Reading J, March MM. The persistence of bacille Calmette–Guerin in the bladder after intravesical treatment of bladder cancer. Br J Urol 1995; 75:199 202.
  • 22
    Ratliff TL, Gillen DP, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 1987; 137:155 8.
  • 23
    Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993; 150:1018 23.
  • 24
    Bohle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD. Effects of local bacillus Calmette–Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990; 144:53 58.
  • 25
    Brinkmann V, Geiger T, Alkan S, Heusser CH. Interferon α increases the frequency of interferon γ-producing human CD4+ T cells. J Exp Med 1993; 178:1655 63.
  • 26
    Brinkmann V, Heusser CH, Baer J, Kilchherr E, Erard F. Interferon α suppresses the capacity of T cells to help antibody production by human B cells. J Interferon Res 1992; 12:267 74.
  • 27
    Borden EC, Groveman DS, Nasu T, Renzikoff C, Bryan GT. Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J Urol 1984; 132:800 3.
  • 28
    Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999; 5:2726 34.
  • 29
    Tzai TS & Lin SN. Interferon-α can alter the lytic susceptibility of murine bladder transitional cell carcinoma (MBT-2) by their original poor specific cytotoxic tumor infiltrating lymphocytes. J Urol 1992; 147:523 7.
  • 30
    Alvarez-Mon M, Molto LM, Manzano L, Olivier C, Carballido JA. Immunomodulatory effect of interferon-alpha 2b on natural killer cells and T lymphocytes from patients with transitional cell carcinoma of the bladder. Anticancer Drugs 1992; 3 (Suppl. 1):5 8.
  • 31
    Wang Z, Cheng Y, Zheng R, Qin D, Liu G. Effect of TNF-alpha and IFN-alpha on the proliferation and cytotoxicity of lymphokine-activated killer cells in patients with bladder cancer. Chin Med J 1997; 110:180 3.
  • 32
    Tilg H & Peschel C. Interferon alpha and its effects on the cytokine cascade: a pro- and anti-inflammatory cytokine. Leuk Lymphoma 1996; 23:55 60.